Kazuhiko Nakaharai1,2, Yohei Sakamoto3, Kenichiro Yaita3,4, Yukihiro Yoshimura3, Shun Igarashi5,6, Natsuo Tachikawa3. 1. Department of Infectious Diseases, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa, 240-8555, Japan. nakaharai@jikei.ac.jp. 2. Department of Infectious Diseases and Infection Control, Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-8461, Japan. nakaharai@jikei.ac.jp. 3. Department of Infectious Diseases, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa, 240-8555, Japan. 4. Department of Infection Control and Prevention, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan. 5. Department of Pharmacy, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa, 240-8555, Japan. 6. Department of Pharmacy, Yokohama Brain and Spine Center, 1-2-1 Takigashira, Isogo-ku, Yokohama, Kanagawa, 235-0012, Japan.
Abstract
PURPOSE: Ceftriaxone has been recognized as a well-tolerated drug; however, in some instances, liver dysfunction occurs after using high-dose ceftriaxone. We aimed to assess the incidence of liver injury due to high-dose ceftriaxone and to determine whether there is a dose-dependent risk of liver injury with this drug. METHODS: We conducted a retrospective cohort study of hospitalized adult patients treated with ceftriaxone at a tertiary care hospital from January 2012 to October 2013. We collected demographic and clinical data by reviewing their medical records. The incidence of liver injury based on biochemical criteria, defined as a primary outcome, was compared between patients treated with high-dose ceftriaxone (4 g/day) and those treated with a normal dose of ceftriaxone (2 g/day) for ≥5 consecutive days. A propensity score for the use of high-dose ceftriaxone was calculated from five factors. RESULTS: We identified 37 patients treated with high-dose ceftriaxone and 434 patients treated with a normal dose of ceftriaxone. Among these 471 patients, 15 patients (3.2 %) experienced liver injury, of whom six patients (6/37, 16.2 %) had received high-dose ceftriaxone and nine patients (9/434, 2.1 %) had received normal doses of ceftriaxone. In the multivariate analysis adjusted for the propensity score, high-dose ceftriaxone was independently associated with liver injury (odds ratio, 7.23; 95 % confidence interval, 2.01-26.0). CONCLUSIONS: The present study revealed that high-dose ceftriaxone was associated with a significantly higher incidence of liver injury compared with the normal-dose regimen. Therefore, clinicians should carefully observe for signs of liver injury after high-dose ceftriaxone use.
PURPOSE:Ceftriaxone has been recognized as a well-tolerated drug; however, in some instances, liver dysfunction occurs after using high-dose ceftriaxone. We aimed to assess the incidence of liver injury due to high-dose ceftriaxone and to determine whether there is a dose-dependent risk of liver injury with this drug. METHODS: We conducted a retrospective cohort study of hospitalized adult patients treated with ceftriaxone at a tertiary care hospital from January 2012 to October 2013. We collected demographic and clinical data by reviewing their medical records. The incidence of liver injury based on biochemical criteria, defined as a primary outcome, was compared between patients treated with high-dose ceftriaxone (4 g/day) and those treated with a normal dose of ceftriaxone (2 g/day) for ≥5 consecutive days. A propensity score for the use of high-dose ceftriaxone was calculated from five factors. RESULTS: We identified 37 patients treated with high-dose ceftriaxone and 434 patients treated with a normal dose of ceftriaxone. Among these 471 patients, 15 patients (3.2 %) experienced liver injury, of whom six patients (6/37, 16.2 %) had received high-dose ceftriaxone and nine patients (9/434, 2.1 %) had received normal doses of ceftriaxone. In the multivariate analysis adjusted for the propensity score, high-dose ceftriaxone was independently associated with liver injury (odds ratio, 7.23; 95 % confidence interval, 2.01-26.0). CONCLUSIONS: The present study revealed that high-dose ceftriaxone was associated with a significantly higher incidence of liver injury compared with the normal-dose regimen. Therefore, clinicians should carefully observe for signs of liver injury after high-dose ceftriaxone use.
Entities:
Keywords:
Adverse drug reactions; Ceftriaxone; Drug-induced liver injury; Hepatotoxicity
Authors: Raúl J Andrade; M Isabel Lucena; M Carmen Fernández; Gloria Pelaez; Ketevan Pachkoria; Elena García-Ruiz; Beatriz García-Muñoz; Rocio González-Grande; Angeles Pizarro; José Antonio Durán; Manuel Jiménez; Luis Rodrigo; Manuel Romero-Gomez; José María Navarro; Ramón Planas; Joan Costa; Africa Borras; Aina Soler; Javier Salmerón; Rafael Martin-Vivaldi Journal: Gastroenterology Date: 2005-08 Impact factor: 22.682
Authors: Einar S Björnsson; Ottar M Bergmann; Helgi K Björnsson; Runar B Kvaran; Sigurdur Olafsson Journal: Gastroenterology Date: 2013-02-16 Impact factor: 22.682
Authors: G P Aithal; P B Watkins; R J Andrade; D Larrey; M Molokhia; H Takikawa; C M Hunt; R A Wilke; M Avigan; N Kaplowitz; E Bjornsson; A K Daly Journal: Clin Pharmacol Ther Date: 2011-05-04 Impact factor: 6.875
Authors: Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon Journal: Gastroenterology Date: 2008-09-17 Impact factor: 22.682
Authors: Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon Journal: Hepatology Date: 2002-08 Impact factor: 17.425
Authors: Nuria Fernández-Hidalgo; Benito Almirante; Joan Gavaldà; Mercè Gurgui; Carmen Peña; Arístides de Alarcón; Josefa Ruiz; Isidre Vilacosta; Miguel Montejo; Nuria Vallejo; Francisco López-Medrano; Antonio Plata; Javier López; Carmen Hidalgo-Tenorio; Juan Gálvez; Carmen Sáez; José Manuel Lomas; Marco Falcone; Javier de la Torre; Xavier Martínez-Lacasa; Albert Pahissa Journal: Clin Infect Dis Date: 2013-02-07 Impact factor: 9.079
Authors: Hans L Tillmann; Ayako Suzuki; Huiman X Barnhart; Jose Serrano; Don C Rockey Journal: Curr Opin Gastroenterol Date: 2019-05 Impact factor: 3.287
Authors: Matteo Guarino; Benedetta Perna; Alessandra Pastorelli; Paolo Bertolazzi; Giacomo Caio; Martina Maritati; Roberto De Giorgio; Carlo Contini Journal: Infez Med Date: 2022-06-01